Charles Sternberg, Associate Editor07.29.22
MiMedx Group Inc., a transformational placental biologics company, has formed a Regenerative Medicine Scientific Advisory Board (RMSAB) to provide guidance on the company’s regenerative medicine clinical pipeline initiatives and support its focus on placental biologics innovation.
The RMSAB, comprised of industry and academic experts across the fields of tissue engineering, osteoarthritis, orthobiologics, musculoskeletal diseases, and regenerative medicine, will provide external scientific and clinical perspectives and high-level counsel on the company’s micronized dehydrated Human Amnion Chorion Membrane (mdHACM) injectable pipeline in Knee Osteoarthritis (KOA), as well as other important indications that could benefit from regenerative medicine therapeutics.
Timothy R. Wright, MiMedx chief executive officer, said, “The prestigious group of thought leaders we have assembled to contribute on our Scientific Advisory Board will provide MiMedx with extensive and recognized expertise as we work to advance a deep and diversified pipeline of a new category of medicine – placental biologics. Working in collaboration with these industry and academic pioneers strengthens our ability to rapidly accelerate scientific innovation, expand our therapeutic potential across multiple indications, and further our vision to advance regenerative science and innovative biologics that restore quality of life for patients in need of safe and effective treatment options.”
Robert B. Stein, M.D., Ph.D., MiMedx President, Regenerative Medicine and Biologics Innovation, added, “These individuals have pioneered significant clinical and scientific contributions in their respective fields. Together, I believe we can accelerate our path forward to registering and developing best-in-class treatment options for patients suffering from osteoarthritis and other debilitating conditions.”
The founding members of the MiMedx Regenerative Medicine Scientific Advisory Board include:
The RMSAB, comprised of industry and academic experts across the fields of tissue engineering, osteoarthritis, orthobiologics, musculoskeletal diseases, and regenerative medicine, will provide external scientific and clinical perspectives and high-level counsel on the company’s micronized dehydrated Human Amnion Chorion Membrane (mdHACM) injectable pipeline in Knee Osteoarthritis (KOA), as well as other important indications that could benefit from regenerative medicine therapeutics.
Timothy R. Wright, MiMedx chief executive officer, said, “The prestigious group of thought leaders we have assembled to contribute on our Scientific Advisory Board will provide MiMedx with extensive and recognized expertise as we work to advance a deep and diversified pipeline of a new category of medicine – placental biologics. Working in collaboration with these industry and academic pioneers strengthens our ability to rapidly accelerate scientific innovation, expand our therapeutic potential across multiple indications, and further our vision to advance regenerative science and innovative biologics that restore quality of life for patients in need of safe and effective treatment options.”
Robert B. Stein, M.D., Ph.D., MiMedx President, Regenerative Medicine and Biologics Innovation, added, “These individuals have pioneered significant clinical and scientific contributions in their respective fields. Together, I believe we can accelerate our path forward to registering and developing best-in-class treatment options for patients suffering from osteoarthritis and other debilitating conditions.”
The founding members of the MiMedx Regenerative Medicine Scientific Advisory Board include:
- Kris Alden, MD, PhD, Orthopaedic Surgeon, Hip, Knee & Shoulder Reconstruction
- Anthony Atala, MD, G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W.H. Boyce Professor and Chair of Urology
- Asger Bihlet, M.Sc., Pharmacy, Chief Scientific Officer, Nordic Bioscience Clinical Development A/S
- Eric Carson, MD, Chair of Orthopaedics, U.S. Veteran’s Hospital, Washington University School of Medicine
- Constance Chu, MD, Professor and Vice Chair Research, Orthopedic Surgery at Stanford University; Director of the Joint Preservation Center and Chief of Sports Medicine at the VA Palo Alto
- Philip Conaghan, MBBS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine; Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine
- Robert Guldberg, PhD, Vice President and Leona DeArmond Executive Director of the Knight Campus for Accelerating Scientific Impact, University of Oregon
- Olga Kubassova, PhD, Chief Executive Officer, Image Analysis Group
- Regis O’Keefe, MD, PhD, Chair of Orthopaedic Surgery, Washington University School of Medicine
- Scott Rodeo, MD, Orthopedic Surgeon and Clinician-Scientist at Hospital for Special Surgery; Professor of Orthopedic Surgery at Weill Cornell Medical College
- Vibeke Strand, MD, Adjunct Clinical Professor, Division of Immunology and Rheumatology, Stanford University School of Medicine
